Sirio Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	4,426	4,184	3,568	2,493	2,331	2,029
Other Revenue	27.4	27.4	13.91	14.19	38.01	37.42
Revenue	4,454	4,211	3,582	2,507	2,369	2,067
Revenue Growth (YoY)	7.90%	17.56%	42.87%	5.84%	14.62%	30.85%
Cost of Revenue	3,023	2,891	2,498	1,737	1,604	1,405
Gross Profit	1,430	1,320	1,085	770.42	764.94	661.56
Selling, General & Admin	868	770.86	628.44	428.27	385.27	306.64
Research & Development	127.82	125.94	110.49	80.72	83.19	64.71
Other Operating Expenses	-4.46	-6.48	-35.8	14.85	14.4	12.82
Operating Expenses	995.05	890.64	708.19	527.83	483.83	387.71
Operating Income	435.24	429.2	376.33	242.59	281.11	273.85
Interest Expense	-97.3	-95.03	-78.48	-42.77	-13.93	-1.8
Interest & Investment Income	7.39	6.89	9.24	34.97	32.18	20.33
Currency Exchange Gain (Loss)	10.86	10.86	20.31	25.49	-18.17	-3.96
Other Non Operating Income (Expenses)	-7	-2.87	-1.28	-1.47	-1.25	-1.6
EBT Excluding Unusual Items	349.19	349.05	326.11	258.81	279.96	286.82
Gain (Loss) on Sale of Investments	-28.08	-26.72	-57.67	-1.64	-1.05	3.95
Gain (Loss) on Sale of Assets	0.47	0.24	0.03	-5.51	0.15	-0.01
Asset Writedown	-11.39	-4.41	-0.95	-	-1.86	-1.39
Other Unusual Items	19.47	-1.51	5.73	-0.15	3.7	22.59
Pretax Income	329.66	316.65	273.26	251.52	280.9	311.96
Income Tax Expense	38.53	34.64	32.97	39.23	49.07	54.6
Earnings From Continuing Operations	291.13	282.02	240.29	212.29	231.83	257.37
Minority Interest in Earnings	54.4	43.04	40.75	-	-	-
Net Income	345.53	325.06	281.04	212.29	231.83	257.37
Net Income to Common	345.53	325.06	281.04	212.29	231.83	257.37
Net Income Growth	2.93%	15.66%	32.39%	-8.43%	-9.92%	80.58%
Shares Outstanding (Basic)	305	304	305	304	304	304
Shares Outstanding (Diluted)	305	304	305	307	322	306
Shares Change (YoY)	0.24%	-0.36%	-0.82%	-4.47%	5.00%	23.77%
EPS (Basic)	1.13	1.07	0.92	0.70	0.76	0.85
EPS (Diluted)	1.13	1.07	0.92	0.69	0.72	0.84
EPS Growth	2.68%	16.08%	33.48%	-4.15%	-14.21%	45.89%
Free Cash Flow	206.27	154.84	-65.62	151.17	-183.31	96.43
Free Cash Flow Per Share	0.68	0.51	-0.21	0.49	-0.57	0.32
Dividend Per Share	0.500	0.500	0.651	0.207	0.237	0.237
Dividend Growth	-23.18%	-23.18%	214.29%	-12.50%	-	200.00%
Gross Margin	32.11%	31.34%	30.28%	30.73%	32.29%	32.01%
Operating Margin	9.77%	10.19%	10.51%	9.68%	11.87%	13.25%
Profit Margin	7.76%	7.72%	7.85%	8.47%	9.79%	12.45%
Free Cash Flow Margin	4.63%	3.68%	-1.83%	6.03%	-7.74%	4.67%
EBITDA	589.63	612.03	597.06	366.95	379.29	353.57
EBITDA Margin	13.24%	14.53%	16.67%	14.64%	16.01%	17.11%
D&A For EBITDA	154.4	182.83	220.73	124.36	98.18	79.72
EBIT	435.24	429.2	376.33	242.59	281.11	273.85
EBIT Margin	9.77%	10.19%	10.51%	9.68%	11.87%	13.25%
Effective Tax Rate	11.69%	10.94%	12.06%	15.60%	17.47%	17.50%
Revenue as Reported	4,454	4,211	3,582	2,507	2,369	2,067
Advertising Expenses	-	12.17	7.8	11.73	31.9	11.26

Source: S&P Global Market Intelligence. Standard template. Financial Sources.